Compare RBB & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBB | IPSC |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.0M | 399.0M |
| IPO Year | 2017 | 2021 |
| Metric | RBB | IPSC |
|---|---|---|
| Price | $23.85 | $2.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $22.00 | $4.25 |
| AVG Volume (30 Days) | 60.7K | ★ 1.1M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | 24.49 | ★ 91.30 |
| EPS | ★ 1.83 | N/A |
| Revenue | $5,167,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $20.50 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $13.07 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $14.68 | $0.44 |
| 52 Week High | $24.73 | $2.97 |
| Indicator | RBB | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 49.59 |
| Support Level | $20.11 | $1.87 |
| Resistance Level | $24.73 | $2.67 |
| Average True Range (ATR) | 0.61 | 0.16 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 68.72 | 26.53 |
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.